NG-618

N/A

Report date: 2026/03/19 16:57:28

Base Information

Drug NameNG-618

Drug Alias Nameanti-CD3/anti-EpCAM bispecific T-cell engager + anti-CD3/anti-FAP bispecific T-cell engager (PsiOxus)transgene-modified enadenotucirev encoding EpTAc and FAPTAc (PsiOxus Therapeutics)NG-618

ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEpithelial cell adhesion molecule modulatorsFibroblast activation protein alpha modulators

TargetsT cell surface glycoprotein CD3Epithelial cell adhesion moleculeProlyl endopeptidase FAP

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAkamis Bio Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAkamis Bio Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A